Publication | Closed Access

Therapeutic Drug Monitoring of the new targeted anticancer agents imatinib, nilotinib, dasatinib, sunitinib, sorafenib and lapatinib by LC tandem mass spectrometry

Therapeutic Drug MonitoringMedicinal ChemistryMedicineMass SpectrometryPharmacologyAnti-cancer AgentCancer TreatmentDrug DevelopmentOncologyRadiation OncologyCancer ResearchDrug DiscoveryDrug Analysis